Diabetes treatment spinout Alms Therapeutics signed up Cap Innov'Est and Morningside Venture Capital as investors after previously tapping regional tech transfer office Satt Conectus for funding.
Alms Therapeutics, a France-based diabetes treatment spinout of University of Strasbourg, closed a €15m ($17.6m) series A round today featuring multi-region seed fund Cap Innov’Est and investment firm Morningside Venture Capital.
Founded in 2017, Alms Therapeutics is working on new drugs to treat type 2 diabetes.
The spinout’s thesis centres on modulating adipocytes – cells programmed to store energy as fat – in the body to help reduce the patient’s blood sugar levels. As it does not involve…